PRCT / PROCEPT BioRobotics Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Second Amendment to Loan and Security Agreement, by and between Canadian Imperial Bank of Commerce and the Registrant, dated as of August 6, 2025

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement is entered into as of August 6, 2025 (the “Amendment”) is entered into between CANADIAN IMPERIAL BANK OF COMMERCE (“Bank”) and PROCEPT BIOROBOTICS CORPORATION, a Delaware corporation (“Borrower Representative”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bio

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance SAN JOSE, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PROCEPT BIOROBOTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO •Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025 •Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif. – July 24, 2025 – PROCEPT BioRobotics (Nas

Employment Agreement, dated July 23, 2025, by and between the Registrant and Larry L. Wood

PROCEPT BIOROBOTICS CORPORATION EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into effective as of July 23, 2025 (the “Execution Date”), is between Larry L.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 PROCEPT BIOROBOTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

Transition Consulting and Retirement Agreement, dated July 23, 2025, by and between the Registrant and Reza Zadno.

TRANSITION CONSULTING AND RETIREMENT AGREEMENT This Transition Consulting and Retirement Agreement (the “Agreement”) by and between Reza Zadno, PhD (“Executive”) and PROCEPT BioRobotics Corporation, a Delaware corporation (the “Company” and, together with Executive, the “Parties”) is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 150 Baytech Drive San Jose, California 95134 (Address of princip

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 PROCEPT BioRobotics Corporation Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 This Conflict Minerals Report (“Report”) of PROCEPT BioRobotics Corporation (“the Company”, “we” or “our”) for the period January 1, 2024 to December 31, 2024 (“the Reporting Period”) has been prepared pursuant to Rule 13p-1, (“Rule 13p-1” or “the Rule”), under t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bi

Form of Performance Stock Unit Agreement under the 2021 Equity Incentive Plan

PROCEPT BIOROBOTICS CORPORATION 2021 EQUITY INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE PROCEPT BioRobotics Corporation, a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Award Plan (as amended from time to time, the “Plan”), has granted to the participant listed below (“Participant”) an award of performance stock units (“Performance Stock Units” or “PSUs”) described in this Performance Stock Unit Award Grant Notice (this “Grant Notice”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

© PROCEPT BioRobotics Corporation. All Rights Reserved. Investor Event 2025 American Urological Association Annual Meeting April 25, 2025 2 Safe Harbor Statement © PROCEPT BioRobotics Corporation. All Rights Reserved. This presentation and accompanyi

© PROCEPT BioRobotics Corporation. All Rights Reserved. Investor Event 2025 American Urological Association Annual Meeting April 25, 2025 2 Safe Harbor Statement © PROCEPT BioRobotics Corporation. All Rights Reserved. This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the ex

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance SAN JOSE, Calif.

Insider Trading Compliance Policy and Procedures.

PROCEPT BioRobotics Corporation Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-043

Fee Filing Table

CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) PROCEPT BioRobotics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock; $0.

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

Non-Employee Director Compensation Program

Exhibit 10.11 PROCEPT BIOROBOTICS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of June 15, 2023) Eligible Directors (as defined below) on the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-043

List of subsidiaries of the Registrant

Exhibit 21.1 LIST OF SUBSIDIARIES OF PROCEPT BIOROBOTICS CORPORATION Subsidiaries Jurisdiction of Incorporation or Organization PROCEPT BioRobotics GmbH Germany PROCEPT BioRobotics UK Ltd. United Kingdom PROCEPT BioRobotics K.K. Japan

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results SAN JOSE, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (

Underwriting Agreement, dated as of October 29, 2024, by and among PROCEPT BioRobotics Corporation, the selling stockholder named therein and BofA Securities, Inc., Piper Sandler & Co. and Morgan Stanely & Co., LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 Execution Version PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 1,923,076 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 29, 2024 PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 1,923,076 Shares of Common Stock UNDERWRITING AGREEMENT October 29, 2024 BofA Securities, Inc. Piper Sandler & Co. Morgan Stanley & Co. LLC as Representatives of the several Un

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

1,923,076 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-273569 PROSPECTUS SUPPLEMENT (To Prospectus dated August 1, 2023) 1,923,076 Shares Common Stock We are offering 1,923,076 shares of our common stock. The selling stockholder has granted the underwriters an option for a period of up to 30 days to purchase up to an additional 288,461 shares of our common stock from them at the public offering pri

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 PROCEPT BioRobotics Corp Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEP

Amended and Restated 2021 Employee Stock Purchase Plan

PROCEPT BIOROBOTICS CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN1 ARTICLE I. PURPOSE The purposes of this PROCEPT BioRobotics Corporation 2021 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of PROCEPT BioRobotics Corporation, a California corporation (the “Company”), and its Designated Subsidiaries in acquiring a stoc

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

EX-99.1 2 prctq32024earningsrelease.htm EX-99.1 PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance SAN JOSE, Calif., October 28, 2024 - PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported u

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

Subject to Completion Preliminary Prospectus Supplement Dated October 28, 2024

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 PROCEPT BIOROBOTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance

PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance SAN JOSE, Calif.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 PROCEPT BIOROBOTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commi

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 PROCEPT BioRobotics Corporation Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report (“Report”) of PROCEPT BioRobotics Corporation (“the Company”, “we” or “our”) for the period January 1, 2023 to December 31, 2023 (“the Reporting Period”) has been prepared pursuant to Rule 13p-1, (“Rule 13p-1” or “the Rule”), under t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 150 Baytech Drive San Jose, California 95134 (Address of princip

PRCT / PROCEPT BioRobotics Corporation / CPMG Inc - SC 13D/A Activist Investment

SC 13D/A 1 ef20029705sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Ln, Suite 100 Dallas, Te

PRCT / PROCEPT BioRobotics Corporation / CPMG Inc - SC 13D/A Activist Investment

SC 13D/A 1 ef20028618sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Ln, Suite 100 Dallas, Te

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commis

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Investor Event 2024 American Urological Association Annual Meeting May 3, 2024 2 Safe Harbor Statement This presentation and accompanying oral presentation contain “forward-looking statemen

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Investor Event 2024 American Urological Association Annual Meeting May 3, 2024 2 Safe Harbor Statement This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corpor

Form of Performance Stock Unit Agreement under the 2021 Equity Incentive Plan

PROCEPT BIOROBOTICS CORPORATION 2021 EQUITY INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE PROCEPT BioRobotics Corporation, a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Award Plan (as amended from time to time, the “Plan”), has granted to the participant listed below (“Participant”) an award of performance stock units (“Performance Stock Units” or “PSUs”) described in this Performance Stock Unit Award Grant Notice (this “Grant Notice”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bi

Non-Employee Director Compensation Program

Exhibit 10.1 PROCEPT BIOROBOTICS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of June 15, 2023) Eligible Directors (as defined below) on the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this

Press Release of PROCEPT BioRobotics Corporation, dated May 1, 2024

PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance SAN JOSE, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

Fee Filing Table

CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) PROCEPT BioRobotics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock; $0.

Compensation Recovery Policy

PROCEPT BIOROBOTICS CORPORATION COMPENSATION RECOVERY POLICY The Board of Directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) has adopted this Compensation Recovery Policy (the “Policy”), effective as of the 60th day following the effectiveness of the Nasdaq Stock Market’s Listing Rule 5608 (the “Effective Date”), in order to foster a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy by facilitating the recovery of erroneously awarded incentive-based compensation upon the occurrence of certain events.

List of subsidiaries of the Registrant

Exhibit 21.1 LIST OF SUBSIDIARIES OF PROCEPT BIOROBOTICS CORPORATION Subsidiaries Jurisdiction of Incorporation or Organization PROCEPT BioRobotics GmbH Germany PROCEPT BioRobotics UK Ltd. United Kingdom PROCEPT BioRobotics K.K. Japan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-043

Non-Employee Director Compensation Program

Exhibit 10.11 PROCEPT BIOROBOTICS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended and restated effective as of June 15, 2023) Eligible Directors (as defined below) on the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (thi

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

Press Release of PROCEPT BioRobotics Corporation, dated February 27, 2024

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results SAN JOSE, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 PROCEPT BIOROBO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (

PRCT / PROCEPT BioRobotics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01739-proceptbioroboticsco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: PROCEPT BioRobotics Corp Title of Class of Securities: Common Stock CUSIP Number: 74276L105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEP

Amended and Restated 2021 Employee Stock Purchase Plan

PROCEPT BIOROBOTICS CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN1 ARTICLE I. PURPOSE The purposes of this PROCEPT BioRobotics Corporation 2021 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of PROCEPT BioRobotics Corporation, a California corporation (the “Company”), and its Designated Subsidiaries in acquiring a stoc

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance SAN JOSE, Calif.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

Underwriting Agreement, dated as of August 1, 2023, by and among PROCEPT BioRobotics Corporation and BofA Securities, Inc., Piper Sandler & Co. and Cowen and Company, LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 Execution Version PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 4,422,169 Shares of Common Stock UNDERWRITING AGREEMENT Dated: August 1, 2023 PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 4,422,169 Shares of Common Stock UNDERWRITING AGREEMENT August 1, 2023 BofA Securities, Inc. Piper Sandler & Co. Cowen and Company, LLC as Representatives of the several Underwri

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) PROCEPT BIOROBOTICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) PROCEPT BIOROBOTICS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities PROCEPT BioRobotics Corporation Equity Common Stock, $0.

4,422,169 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-273569 PROSPECTUS SUPPLEMENT (To Prospectus dated August 1, 2023) 4,422,169 Shares Common Stock We are offering 4,422,169 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “PRCT.” On July 31, 2023, the last reported sale price of our common stock on the Nasdaq Global Market was $34.44 per share.

Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association, as trustee under the indenture filed as Exhibit 4.2 above.

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

As filed with the Securities and Exchange Commission on August 1, 2023

As filed with the Securities and Exchange Commission on August 1, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Exhibit 107 Form S-3 (Form Type) PROCEPT BioRobotics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount

Form of Indenture.

Exhibit 4.2 PROCEPT BIOROBOTICS CORP. INDENTURE Dated as of , 20 U.S. Bank Trust Company, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 5 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 6 ARTICLE II. THE SECURITIES 6 Section

Subject to Completion Preliminary Prospectus Supplement Dated August 1, 2023

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 PROCEPT BIOROBOTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance REDWOOD CITY, Calif.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commi

First Amendment to Loan and Security Agreement, by and between Canadian Imperial Bank of Commerce and the Registrant, dated June 1, 2023

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement is entered into as of June 1, 2023, (the “Amendment”) is entered into between CANADIAN IMPERIAL BANK OF COMMERCE (“Bank”) and PROCEPT BIOROBOTICS CORPORATION, a Delaware corporation (“Borrower Representative”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bi

Offer Letter, by and between the Registrant and Alaleh Nouri, dated as of May 15, 2018

Exhibit 10.18 May 15, 2018 Alaleh Nouri 171 Main Street #115 Los Altos, CA 94022 Re: Employment Terms Dear Alaleh: On behalf of PROCEPT BioRobotics Corporation (the "Company"), I am very pleased to offer you the position of Senior Vice President, General Counsel and Corporate Secretary of the Company, reporting to me. This letter agreement sets forth the terms and conditions of your employment wit

Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Alaleh Nouri, dated September 17, 2021

Exhibit 10.19 PROCEPT BioRobotics Corporation Amended and Restated Change Of Control And Severance Agreement This Amended and Restated Change of Control and Severance Agreement (this “Agreement”) is entered into effective as of September 17, 2021 (the “Effective Date”) by and between Alaleh Nouri (“Executive”) and PROCEPT BioRobotics Corporation, a Delaware corporation (the “Company”). Recital The

1 INVESTOR EVENT 2023 American Urology Association Annual Meeting April 28, 2023 C o p y r i g h t 2 0 2 3 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . 2 Safe Harbor Statement This presentation and a

final2023auadeck 1 INVESTOR EVENT 2023 American Urology Association Annual Meeting April 28, 2023 C o p y r i g h t 2 0 2 3 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n .

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PROCEPT BIOROBOTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2022 Results

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2022 Results REDWOOD CITY, Calif.

Fee Filing Table

CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) PROCEPT BioRobotics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock; $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-043

Confidential Exclusive Patent License and Covenant Not to Sue, by and between the Registrant and HydroCision, Inc., dated March 14, 2019

Exhibit 10.17 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant treats as private or confidential. CONFIDENTIAL EXCLUSIVE PATENT LICENSE AND COVENANT NOT TO SUE This Confidential Exclusive Patent License and Covenant Not to Sue (the “Agreement”) is entered into as o

As filed with the Securities and Exchange Commission on February 28, 2023

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

rth Amendment to Lease Agreement, by and between the Registrant and Westport Office Park LLC, dated as of January 27, 2023.

Exhibit 10.7(d) FOURTH AMENDMENT TO LEASE (EXTENSION) This Forth Amendment to Lease (the "Agreement") is entered into as of January 27, by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company ("Landlord"), and PROCEPT BIOROBOTICS CORPORATION, a Delaware corporation ("Tenant"), with respect to the following facts and circumstances: Landlord (as successor by conversion to betw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 PROCEPT BIOROBO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (

PRCT / Procept BioRobotics Corp / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047952sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) PROCEPT BioRobotics Corporation (Name of Issuer) Common stock, $0.00001 par value p

PRCT / Procept BioRobotics Corp / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: PROCEPT BioRobotics Corp. Title of Class of Securities: Common Stock CUSIP Number: 74276L105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PROCEPT BIOROBOTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Co

PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28, 2023

PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28, 2023 REDWOOD CITY, Calif.

PRCT / Procept BioRobotics Corp / CPMG Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Ln, Suite 100 Dallas, Texas 75209 214-871-6816 (Name, Address and

PRCT / Procept BioRobotics Corp / CPMG Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Ln, Suite 100 Dallas, Texas 75209 214-871-6816 (Name, Address and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEP

PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance REDWOOD CITY, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Co

each Borrower and Guarantor from time to time

Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of October 6, 2022 (the ?Closing Date?) is entered into among CANADIAN IMPERIAL BANK OF COMMERCE (?Bank?), PROCEPT BIOROBOTICS CORPORATION, a Delaware corporation (?Borrower Representative?) and each Borrower and Guarantor

PRCT / Procept BioRobotics Corp / CPMG Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 2000 McKinney Ave, Suite 2125 Dallas, Texas 75201 214-871-6816 (Name, Address and

PRCT / Procept BioRobotics Corp / CPMG Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 2000 McKinney Ave, Suite 2125 Dallas, Texas 75201 214-871-6816 (Name, Address and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Com

PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance REDWOOD CITY, Calif.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commi

1 © 2 0 2 2 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . ML0447.A INVESTOR EVENT 2022 American Urology Association Annual Meeting May 13, 2022 2 © 2 0 2 2 P R O C E P T B i o R o b o t i c s C o r p

1 ? 2 0 2 2 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . ML0447.A INVESTOR EVENT 2022 American Urology Association Annual Meeting May 13, 2022 2 ? 2 0 2 2 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . ML0447.A Safe Harbor Statement This presentation contains ?forward-looking statements? within the

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commi

Fee Filing Table

CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) PROCEPT BioRobotics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Type Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock; $0.

As filed with the Securities and Exchange Commission on May 6, 2022

As filed with the Securities and Exchange Commission on May 6, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT Bi

PROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

PROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance REDWOOD CITY, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-043

PRCT / Procept BioRobotics Corp / VIKING GLOBAL INVESTORS LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* PROCEPT BioRobotics Corporation (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 742

Third Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance LLC, dated as of January 7, 2022

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of January 7, 2022 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Schedule 1.

Description of PROCEPT BioRobotics Corporation’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE EXCHANGE ACT The following descriptions of the common stock of PROCEPT BioRobotics Corporation (the ?Company,? ?we,? ?us,? and ?our?) and certain provisions of our amended and restated certificate of incorporation, as amended from time to time (the ?amended and restated certificate of incorporation?) and amended and res

Lease, by and between the Registrant and 150-180 Baytech Drive CA Owner, LLC, dated December 31, 2021

LEASE BY AND BETWEEN 150-180 BAYTECH DRIVE CA OWNER LLC, a Delaware limited liability company as Landlord and PROCEPT BIOROBOTICS CORPORATION, a Delaware corporation as Tenant For Premises located at 150-160 Baytech Drive, San Jose, California LEASE This Lease is dated as of the date specified in Section A of the Summary of Basic Lease Terms ("Summary") and is made by and between the party identified as Landlord in Section B of the Summary and the party identified as Tenant in Section C of the Summary.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Comm

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial Results

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial Results REDWOOD CITY, Calif.

PRCT / Procept BioRobotics Corp / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* PROCEPT BioRobotics Corporation (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 742

PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue REDWOOD CITY, Calif., January 11, 2022 - PROCEPT? BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 20

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (

Press Release of PROCEPT BioRobotics Corporation, dated

PROCEPT BioRobotics Appoints Mary Garrett to Board of Directors REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEP

PROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance

PROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance REDWOOD CITY, Calif., November 4, 2021 - PROCEPT? BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the quarter ended September 30, 2021. Recent Highlight

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors

PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors REDWOOD CITY, Calif.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (C

PRCT / Procept BioRobotics Corp / VIKING GLOBAL INVESTORS LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* PROCEPT BioRobotics Corporation (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 74276L105 (CUSIP Numb

PRCT / Procept BioRobotics Corp / CPMG Inc - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* PROCEPT BioRobotics Corporation (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74276L105 (CUSIP Number) John Bateman CPMG, Inc. 2000 McKinney Ave, Suite 2125 Dallas, Texas 75201 214-871-6816 (Name, Address and T

Amended and Restated Bylaws

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 1 2.5 ADVANCE NOTICE PROCE

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation)

Amended and Restated Certificate of Incorporation,

Exhibit 3.1 PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION PROCEPT BioRobotics Corporation, a Delaware corporation, hereby certifies as follows: 1.The name of the Corporation is PROCEPT BioRobotics Corporation. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on January 29, 2021. 2.The Ame

6,556,000 Shares Common Stock

Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-258898 and 333-259527 6,556,000 Shares Common Stock This is an initial public offering of shares of common stock of PROCEPT BioRobotics Corporation. We are selling 6,556,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock is $25.00

As filed with the Securities and Exchange Commission on September 16, 2021

As filed with the Securities and Exchange Commission on September 16, 2021 Registration No.

As filed with the Securities and Exchange Commission on September 14, 2021

As filed with the Securities and Exchange Commission on September 14, 2021 Registration No.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Delaware 26-0199180 (State or incorporation or organization) (I.R.S. Employer Identification No.) 900 Island D

[signature page follows]

September 10, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

PROCEPT BioRobotics Corporation 900 Island Drive Redwood City, CA 94065

PROCEPT BioRobotics Corporation 900 Island Drive Redwood City, CA 94065 September 10, 2021 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

the Amended and Restated

Exhibit 10.4(a) PROCEPT BIOROBOTICS CORPORATION 2008 STOCK PLAN NOTICE OF STOCK OPTION GRANT (EARLY EXERCISE PERMITTED) ?HolderName? You have been granted an option to purchase Common Stock of PROCEPT BioRobotics Corporation (the ?Company?) as follows: Board Approval Date: ?BoardApprovalDate? Date of Grant (Later of Board Approval Date or Commencement of Employment/Consulting): ?GrantDate? Exercis

Amended and Restated Bylaws, as in effect upon the closing of the initial public offering

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 1 2.5 ADVANCE NOTICE PROCE

Form of Stock Option Agreement under the 2021 Equity Incentive Award Plan

Exhibit 10.11(a) PROCEPT BIOROBOTICS CORPORATION 2021 EQUITY INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE PROCEPT BioRobotics Corporation, a Delaware corporation (the ?Company?) has granted to the participant listed below (?Participant?) the stock option (the ?Option?) described in this Stock Option Grant Notice (the ?Grant Notice?), subject to the terms and conditions of the PROCEPT BioRobotics

Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Kevin Waters,

Exhibit 10.14 PROCEPT BioRobotics Corporation Amended and Restated Change Of Control And Severance Agreement This Amended and Restated Change of Control and Severance Agreement (this ?Agreement?) is entered into effective as of [l], 2021 (the ?Effective Date?)1 by and between Kevin Waters (?Executive?) and PROCEPT BioRobotics Corporation, a California corporation (the ?Company?). Recital The Compa

Form of Indemnification

Exhibit 10.5 PROCEPT BIOROBOTICS CORPORATION INDEMNIFICATION AND ADVANCEMENT AGREEMENT THIS INDEMNIFICATION AND ADVANCEMENT AGREEMENT (?Agreement?) is effective as of [], 2021, by and between PROCEPT BioRobotics Corporation, a Delaware corporation (the ?Company?), and the undersigned individual (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Compa

Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Reza Zadno, Ph.D.,

Exhibit 10.13 PROCEPT BIOROBOTICS CORPORATION Amended and Restated Change Of Control And Severance Agreement This Amended and Restated Change of Control and Severance Agreement (this ?Agreement?) is entered into effective as of [l], 2021 (the ?Effective Date?)1 by and between Reza Zadno, PhD (?Executive?) and PROCEPT Biorobotics Corporation, a California corporation (the ?Company?). Recital The Co

2021 Employee Stock Purchase Plan

Exhibit 10.12 PROCEPT BIOROBOTICS CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this PROCEPT BioRobotics Corporation 2021 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of PROCEPT BioRobotics Corporation, a California corporation (the ?Company?), and its Designated Subsidiaries in acq

650 Town Center Drive, 20th Floor

650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County September 8, 2021 Chicago Paris Dubai Riyadh D?sseldorf San Diego VIA EDGAR Frankfurt San Francisco Hamburg Seoul Division of Corporation Finance Office of Trade & Services United

Form of Underwriting Agreement.

Exhibit 1.1 PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) [l] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [l], 2021 PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT [?], 2021 BofA Securities, Inc. Goldman Sachs & Co. LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, Ne

Amended and Restated Certificate of Incorporation, as in effect upon the closing of the initial public offering

Exhibit 3.1 PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION PROCEPT BioRobotics Corporation, a Delaware corporation, hereby certifies as follows: 1.The name of the Corporation is PROCEPT BioRobotics Corporation. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on January 29, 2021. 2.The Ame

As filed with the Securities and Exchange Commission on September 8, 2021

As filed with the Securities and Exchange Commission on September 8, 2021 Registration No.

Non-Employee Director Compensation

Exhibit 10.10 PROCEPT BIOROBOTICS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Eligible Directors (as defined below) on the board of directors (the ?Board?) of PROCEPT BioRobotics Corporation (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described

2021 Equity Incentive Award Plan

Exhibit 10.11 PROCEPT BIOROBOTICS CORPORATION 2021 EQUITY INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms

Form of Restricted Stock Unit Agreement under the 2021 Equity Incentive Award Plan

Exhibit 10.11(b) PROCEPT BIOROBOTICS CORPORATION 2021 EQUITY INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE PROCEPT BioRobotics Corporation, a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and condition

Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Hisham Shiblaq,

Exhibit 10.15 PROCEPT BioRobotics Corporation Amended and Restated Change Of Control And Severance Agreement This Amended and Restated Change of Control and Severance Agreement (this ?Agreement?) is entered into effective as of [l], 2021 (the ?Effective Date?)1 by and between Hisham Shiblaq (?Executive?) and PROCEPT BioRobotics Corporation, a California corporation (the ?Company?). Recital The Com

Amended and Restated 2008 Stock Plan.

Exhibit 10.4 PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED 2008 STOCK PLAN As of July 20, 2020 1. Purposes of the Plan. The purposes of this Amended and Restated 2008 Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants and to promote the success of the Company?s business.

FOIA Confidential Treatment Requested Under 17 C.F.R. § 200.83

650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Beijing Boston Munich Brussels New York Century City Orange County August 31, 2021 Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid W

Power of Attorney

As filed with the Securities and Exchange Commission on August 18, 2021 Registration No.

Offer Letter, by and between the Registrant and Reza Zadno, Ph.D., dated as of January 31, 2020

Exhibit 10.1 PROCEPT BIOROBOTICS January 31, 2020 Reza Zadno, Ph.D. Dear Reza, On behalf of PROCEPT BioRobotics Corporation (the ?Company?) I am pleased to offer you the position of President, Chief Executive Officer, and member of the Board of Directors of the Company. You will report to the Board of Directors of the Company (the ?Board?) and you will be responsible for the overall direction of t

Loan and Security Agreement, by and between the Registrant and Oxford Finance LLC, dated as of September 25, 2019.

Exhibit 10.7 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of September 25, 2019 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral age

Second Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance LLC, dated as of April 6, 2021.

Exhibit 10.7 (b) CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 6, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (in its individual capacity

Offer Letter, by and between the Registrant and Hisham Shiblaq, dated as of March 21, 2019

Exhibit 10.3 March 21, 2019 Hisham Shiblaq Via Email Re: Employment Terms Dear Sham: PROCEPT BIOBOTICS CORPORATION (the ?Company?) is pleased to offer you the position of Senior Vice President, Commercial Operations, on the following terms. You will be responsible for leading the commercial sales and marketing organization and will report to the President and CEO. You will work at our facility loc

Lease, by and between the Registrant and 150-180 Baytech Drive CA Owner, LLC, dated December 31, 2021

Exhibit 10.8 LEASE AGREEMENT By and Between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?) and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?) July 15, 2013 TABLE OF CONTENTS Page ARTICLE 1. PREMISES; COMMON AREAS 3 ARTICLE 2. TERM AND CONDITION OF PREMISES 4 ARTICLE 3. USE, NUISANCE, OR HAZARD 5 ARTICLE 4. RENT 6 ARTICLE 5. RENT ADJUSTMENT 9 AR

Amended and Restated Exclusive License Agreement, by and between the Registrant and AquaBeam LLC, dated as of September 13, 2019

Exhibit 10.6 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated Exclusive License Agreement (this ?Agreement?) is effective as of September 13, 2019 (the ?Effective Date?) by and between AquaBeam LLC, a California limited liability company having offices at 2995 Woodside Road, Suite 100, Woodside, California 94062 (?AquaBeam?), and PROCEPT BioRobotics Corporation, a Califor

Amended and Restated Investor Rights Agreement, by and among the Registrant and the investors named therein and the founder named therein, dated June 10, 2021

Exhibit 10.9 PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the ?Agreement?) is entered into as of June 10, 2021, by and among PROCEPT BioRobotics Corporation, a Delaware corporation (the ?Company?), the investors listed on Exhibit A hereto (each, an ?Investor? and collectively, the ?Investors?), and the Founders

Third Amendment to Lease Agreement, by and between the Registrant and Westport Office Park LLC, dated as of April 4, 2018

Exhibit 10.8(c) THIRD AMENDMENT TO LEASE (EXPANSION) This Third Amendment to Lease (the ?Agreement?) is entered into as of April 4, 2018 by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?), with respect to the following facts and circumstances: A. Landlord and Tenant are parties to t

Second Amendment to Lease Agreement, by and between the Registrant and Westport Office Park LLC, dated as of May 20, 2016

Exhibit 10.8(b) SECOND AMENDMENT TO LEASE This Second Amendment to Lease (the ?Agreement?) is entered into as of May 20, 2016, by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?), with respect to the following facts and circumstances: A. Landlord and Tenant are parties to that certai

First Amendment to Lease Agreement, by and between the Registrant and Westport Office Park LLC, dated as of March 2, 2016

Exhibit 10.8(a) FIRST AMENDMENT TO LEASE (EXPANSION) This First Amendment to Lease (the ?Agreement?) is entered into as of March 2, 2016 by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?), with respect to the following facts and circumstances: A. Landlord and Tenant are parties to t

First Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance LLC, dated as of January 15, 2021.

Exhibit 10.7 (a) FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of January 15, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity,

Offer Letter, by and between the Registrant and Kevin Waters, dated as of August 7, 2018

Exhibit 10.2 PROCEPT BIOROBOTICS August 7, 2018 Kevin Waters Re: Employment Terms Dear Kevin: On behalf of PROCEPT BioRobotics Corporation (the ?Company?), I am very pleased to offer you the position of Chief Financial Officer of the Company, reporting to me. This letter agreement sets forth the terms and conditions of your employment with the Company. Please understand that this offer, if not acc

650 Town Center Drive, 20th Floor

650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County August 18, 2021 Chicago Paris Dubai Riyadh D?sseldorf San Diego VIA EDGAR Frankfurt San Francisco Hamburg Seoul Division of Corporation Finance Office of Trade & Services United St

List of subsidiaries of the Registrant

Exhibit 21.1 LIST OF SUBSIDIARIES OF PROCEPT BIOROBOTICS CORPORATION Subsidiaries Jurisdiction of Incorporation or Organization PROCEPT BioRobotics GmbH Germany PROCEPT BioRobotics UK Ltd. United Kingdom

1

Exhibit 10.3 March 21, 2019 Hisham Shiblaq Via Email Re: Employment Terms Dear Sham: PROCEPT BIOBOTICS CORPORATION (the ?Company?) is pleased to offer you the position of Senior Vice President, Commercial Operations, on the following terms. You will be responsible for leading the commercial sales and marketing organization and will report to the President and CEO. You will work at our facility loc

CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

Exhibit 10.7 (b) CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 6, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (in its individual capacity

THIRD AMENDMENT TO LEASE

Exhibit 10.8(c) THIRD AMENDMENT TO LEASE (EXPANSION) This Third Amendment to Lease (the ?Agreement?) is entered into as of April 4, 2018 by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?), with respect to the following facts and circumstances: A. Landlord and Tenant are parties to t

This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted with the Securities and Exchange Commission on July 29, 20

This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.

LOAN AND SECURITY AGREEMENT

EX-10.7 11 filename11.htm Exhibit 10.7 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of September 25, 2019 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“O

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.6 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated Exclusive License Agreement (this ?Agreement?) is effective as of September 13, 2019 (the ?Effective Date?) by and between AquaBeam LLC, a California limited liability company having offices at 2995 Woodside Road, Suite 100, Woodside, California 94062 (?AquaBeam?), and PROCEPT BioRobotics Corporation, a Califor

PROCEPT

Exhibit 10.1 PROCEPT BIOROBOTICS January 31, 2020 Reza Zadno, Ph.D. Dear Reza, On behalf of PROCEPT BioRobotics Corporation (the ?Company?) I am pleased to offer you the position of President, Chief Executive Officer, and member of the Board of Directors of the Company. You will report to the Board of Directors of the Company (the ?Board?) and you will be responsible for the overall direction of t

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

Exhibit 10.7 (a) FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of January 15, 2021 (the ?Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity,

PROCEPT

Exhibit 10.2 PROCEPT BIOROBOTICS August 7, 2018 Kevin Waters Re: Employment Terms Dear Kevin: On behalf of PROCEPT BioRobotics Corporation (the ?Company?), I am very pleased to offer you the position of Chief Financial Officer of the Company, reporting to me. This letter agreement sets forth the terms and conditions of your employment with the Company. Please understand that this offer, if not acc

PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

EX-10.9 13 filename13.htm Exhibit 10.9 PROCEPT BIOROBOTICS CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of June 10, 2021, by and among PROCEPT BioRobotics Corporation, a Delaware corporation (the “Company”), the investors listed on Exhibit A hereto (each, an “Investor” and collectively, the “Inve

FIRST AMENDMENT TO LEASE

Exhibit 10.8(a) FIRST AMENDMENT TO LEASE (EXPANSION) This First Amendment to Lease (the ?Agreement?) is entered into as of March 2, 2016 by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?), with respect to the following facts and circumstances: A. Landlord and Tenant are parties to t

LEASE AGREEMENT By and Between WESTPORT OFFICE PARK, LLC, a California limited liability company PROCEPT BIOROBOTICS CORPORATION, a California corporation July 15, 2013

Exhibit 10.8 LEASE AGREEMENT By and Between WESTPORT OFFICE PARK, LLC, a California limited liability company (?Landlord?) and PROCEPT BIOROBOTICS CORPORATION, a California corporation (?Tenant?) July 15, 2013 TABLE OF CONTENTS Page ARTICLE 1. PREMISES; COMMON AREAS 3 ARTICLE 2. TERM AND CONDITION OF PREMISES 4 ARTICLE 3. USE, NUISANCE, OR HAZARD 5 ARTICLE 4. RENT 6 ARTICLE 5. RENT ADJUSTMENT 9 AR

SECOND AMENDMENT TO LEASE

EX-10.8B 5 filename5.htm Exhibit 10.8(b) SECOND AMENDMENT TO LEASE This Second Amendment to Lease (the “Agreement”) is entered into as of May 20, 2016, by and between WESTPORT OFFICE PARK, LLC, a California limited liability company (“Landlord”), and PROCEPT BIOROBOTICS CORPORATION, a California corporation (“Tenant”), with respect to the following facts and circumstances: A. Landlord and Tenant a

Beijing Moscow

DRSLTR 1 filename1.htm 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shangai Houston Silicon Valley London Singapore Los Angeles T

This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted with the Securities and Exchange Commission on June 25, 20

DRS 1 filename1.htm This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted with the Securities and Exchange Commission on June 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT U